William Blair Reiterates Outperform Rating on Biohaven Pharmaceutical (BHVN), Sees Nurtec ODT as Leader in Migraine Therapies
Tweet Send to a Friend
William Blair analyst Tim Lugo reiterated an Outperform rating on Biohaven Pharmaceutical Holding (NYSE: BHVN)ю The analyst comments: "We view ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
